In This Article:
How much a stock's price changes over time is important for most investors, since price performance can both impact your investment portfolio and help you compare investment results across sectors and industries.
The fear of missing out, or FOMO, also plays a factor in investing, especially with particular tech giants, as well as popular consumer-facing stocks.
What if you'd invested in Zoetis (ZTS) ten years ago? It may not have been easy to hold on to ZTS for all that time, but if you did, how much would your investment be worth today?
Zoetis' Business In-Depth
With that in mind, let's take a look at Zoetis' main business drivers.
Florham Park, NJ-based Zoetis Inc. came into existence following Pfizer’s decision to spin off its animal health business. The entity started trading on NYSE on Feb 1, 2013, under the name Zoetis. The company is a leader in the animal health space with a focus on both livestock and companion animals in seven major product categories: vaccines, anti-infectives, parasiticides, dermatology, other pharmaceutical products, medicated feed additives and animal health diagnostics. Zoetis has a diversified business, which caters to eight core species — cattle, swine, poultry, fish and sheep (collectively, livestock) and dogs, cats and horses (collectively, companion animals).
The outstanding growth rate in the companion animal medicines, vaccines and diagnostics sector is being driven by economic development, related increases in disposable income and a rise in pet ownership and spending on pet care.
Zoetis has been working on strengthening its product portfolio through acquisitions and deals. In 2022, the company completed the acquisition of Jurox, an animal health company based in Australia, which brings the company a range of companion animal and livestock products and provides the company with future growth opportunities, manufacturing capacity and increased capabilities in Australia. Also in 2022, the company acquired Basepaws, a petcare genetics company that provides pet owners with genetic tests, analytics and early health risk assessments, which help pet owners and veterinarians understand an individual pet’s risk for disease and can lead to more meaningful engagements and increased likelihood of early detection and treatment of disease.
Zoetis has consolidated its four-region structure into a two-region structure, namely the United States and International. Total revenues grew 4% year over year to $8.1 billion in 2022. The United States contributed 53% of total revenues in 2022 while international revenues contributed the rest.
In 2022, Zoetis’ two top-selling products and product lines were Simparica/Simparica Trio and Apoquel, which contributed approximately 12% and 10%, respectively, of its revenue. Also in 2022, Zoetis recorded 15 products and product lines with revenues of $100 million or more.